Skip to content

MRI in Renal Transplantation

Non Contrast Magnetic Resonance Imaging to Measure Renal Transplant Perfusion and Fibrosis - Association With Function and Prognosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03705091
Acronym
TransRASL
Enrollment
20
Registered
2018-10-15
Start date
2017-04-11
Completion date
2019-03-20
Last updated
2018-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases, End Stage Renal Disease, Kidney Transplant Failure and Rejection, Renal Transplant Rejection

Keywords

Magnetic resonance imaging, Biomarkers, Arterial spin labelling, Diffusion weighted imaging, Renal transplantation

Brief summary

Renal transplantation is the optimal method of treatment for end stage kidney disease however median lifespan of a kidney transplant is around 15 years. Existing methods of measuring transplant function and structure from blood and urine markers are imperfect; renal biopsy is often performed but is invasive. Novel methods of investigating transplant function are therefore required and emerging renal MRI sequences including ASL and diffusion weighted imaging may yield helpful biomarkers. Investigators will recruit 20 patients in the first year after transplant and measure MRI biomarkers at three time points, with correlation to existing methods of measuring transplant function.

Detailed description

Kidney transplantation remains the optimal therapy for patients with end stage kidney disease and is associated with significant improvements in life expectancy and quality of life compared to subjects receiving dialysis. Despite significant advances in our understanding of the immune system and development of drugs to prolong transplant function, a large number (Scottish Renal Registry data suggest between 23-35%) of transplants fail in the 10 years from operation. This may be due to a number of factors but is often due to development of transplant rejection, where the recipient's immune system damages the transplant. Early recognition and implementation of therapy is needed to dampen this response, reduce irreversible damage and preserve transplant function. At present, transplant function and damage is measured using blood and urine tests. These are far from perfect markers because there is a delay between transplant damage and abnormalities of these tests. This time is vital for the short and long term survival of the transplant. In the University of Glasgow, investigators have developed a new type of magnetic resonance imaging (MRI) which allows assessment of kidney blood flow and fibrosis (scarring) without the need for administration of harmful contrast agents. Arterial spin labelling magnetic resonance imaging (ASL MRI) is a non-invasive method of measuring renal perfusion using magnetised blood as endogenous contrast and investigators have validated this technique previously in both individuals with and without kidney disease. Diffusion tensor imaging (DTI) is another modality of non-contrast MRI which allows measurement of 'stiffness' of renal transplants, which represents long term scarring and fibrosis. The investigators intend to follow up people receiving a kidney transplant for one year, collecting samples of blood, urine, and performing MR imaging at 3 time points, in order to investigate novel biomarkers of transplant function and dysfunction.

Interventions

DIAGNOSTIC_TESTMagnetic resonance imaging

ASL and DWI MRI

Sponsors

NHS Greater Glasgow and Clyde
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years * Recent or pending kidney transplantation * Written informed consent

Exclusion criteria

* Severe chronic liver, heart or lung disease * Chronic infection * Unable to give valid informed consent * Known pregnancy or intent to conceive during the study period * Any contraindicating to MRI

Design outcomes

Primary

MeasureTime frameDescription
Change in arterial spin labelling (ASL)Measured at 2, 6, 12 months after transplantRenal perfusion measured by ASL MRI

Secondary

MeasureTime frameDescription
Change in apparent diffusion coefficient (ADC)Measured at 2, 6, 12 months after transplantRenal fibrosis measured by diffusion weighted imaging (DWI) MRI

Countries

United Kingdom

Contacts

Primary ContactKeith Gillis, MBChB PhD
keithgillis@nhs.net0141 330 2409

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026